查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1868924

核酸類藥物市場：2025-2032年全球預測（按藥物類型、分子類型、給藥途徑、治療領域和最終用戶分類）

Nucleic Acid-Based Drugs Market by Drug Type, Molecule Type, Route of Administration, Therapeutic Area, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，核酸藥物市場將成長至 934.6 億美元，複合年成長率為 13.73%。

關鍵市場統計數據
基準年 2024 333.7億美元
預計年份：2025年 377.6億美元
預測年份 2032 934.6億美元
複合年成長率 (%) 13.73%

科學突破、監管成熟度和產業規模匯聚成一份簡潔的核酸療法策略指南。

核酸療法已從小眾研究領域發展成為現代藥物研發的主流支柱，這主要得益於遞送系統、化學修飾和法規核准的突破。近期臨床成功案例和核准途徑驗證了曾經備受質疑的療法的有效性，也促使科學界更加關注mRNA、 RNA干擾和反義技術的可擴展應用。這些進展正在重塑研發人員選擇標靶、進行患者分層和評估平台經濟性的方式，從而加快從藥物發現到首次人體臨床試驗的週期。

技術平台化、監管明確化和供應鏈韌性正在推動變革，重新定義核酸治療領域的競爭力和專案可行性。

核酸療法領域經歷了變革性的變化，重新定義了競爭優勢和專案可行性。技術的成熟，尤其是在遞送載體、脂質奈米顆粒化學和精確化學修飾方面的進步，已將許多以往難以攻克的標靶轉化為可行的治療選擇。同時，平台思維發揮了核心作用，各機構建立可重複使用的開發框架，以縮短後續候選藥物的開發週期並降低技術風險。這種平台化改變了投資模式，資本越來越傾向於投資那些擁有成熟轉換路徑的公司，而非孤立的治療概念。

評估關稅趨勢如何推動核酸治療藥物供應鏈區域化、成本重新分配以及採購和製造方面的策略轉變

貿易政策變化和關稅上調的前景將對核酸研發商和供應商的經濟狀況和商業計劃產生累積影響。進口關稅的提高會影響關鍵原料的成本，例如修飾核苷酸、脂質組分、層析法樹脂和專用一次性耗材。上游工程原料成本的上漲迫使企業重新分配預算，優先考慮具有明確價值提案的項目，或加快供應鏈本地化，以維持利潤率和進度穩定性。

深度細分分析將藥物模式、分子類別、給藥途徑、治療領域和終端用戶行為與策略性研發和商業化選擇聯繫起來。

細分分析揭示了不同治療模式、分子類別、給藥途徑、治療領域和最終用戶之間存在的顯著差異，因此需要採取差異化策略。基於藥物類型，研發人員必須平衡反義寡核苷酸、DNA/RNA適體、mRNA療法、核苷類似物和RNA干擾療法各自的技術要求，其中RNA干擾療法又可進一步細分為微型RNA、短髮夾RNA和短干擾RNA。注重模組化化學和遞送方法的平台投資有望開發出該頻譜內的多種亞型。基於分子類型的決策框架因分子大小而異，這會影響生產複雜性、分析控制策略和儲存物流。

美洲、歐洲、中東和非洲以及亞太地區的區域優勢和監管差異將決定創新、製造和商業化將在哪些地區加速發展。

區域趨勢決定了創新、生產和商業化動力將在何處匯聚，因​​此需要在美洲、歐洲、中東和非洲以及亞太地區制定具有地域針對性的策略。在美洲，生技產業叢集密集、資本充足且監管靈活，這些因素共同促進了早期創新蓬勃發展，並推動了夥伴關係與衍生公司的活躍交易。隨著臨床試驗基礎設施和病患招募效率的提高，國內製造投資日益受到重視，有助於快速概念驗證研究，並有效管理供應鏈和關稅風險。

加速開發、實現擴充性和獲取商業性價值所需的公司類型和夥伴關係

競爭格局是一個複雜而密集的生態系統，由垂直整合的開發商、專業平台提供者、合約開發和生產組織 (CDMO) 以及試劑和儀器供應商組成。領先的開發商憑藉其平台的可重複性、經證實的臨床記錄以及建立戰略合作夥伴關係以降低後期開發風險的能力而脫穎而出。提供遞送系統、新型化學方法和先進分析技術的專業平台公司正獲得特別的優勢，因為它們能夠支援多個治療項目並降低合作夥伴的技術不確定性。

為領導者提供高影響力建議，幫助他們將技術進步轉化為營運韌性、監管應對力和商業性可行性。

行業領導者應採取有針對性的策略，將科學基礎與營運韌性和商業性清晰度相結合。首先，優先投資於能夠實現跨適應症和治療方式重複使用的平台。這些平台將降低研發風險，並加速下一代專案的推進。其次，提高供應鏈透明度，實現關鍵材料供應商多元化，同時探索區域製造夥伴關係，以降低關稅和物流風險。第三，在專案設計初期就整合監管和品質方面的專業知識，以簡化對比測試、上市前測試和CMC（化學、生產和品管）流程。

我們採用透明的多方法調查方法，結合專家訪談、技術文獻、監管審查和情境分析來檢驗關鍵發現。

本摘要的研究採用了一種多方面的方法，結合了一手和二手資料，以確保其可靠性和相關性。一手資料包括對開發人員、生產專家和監管專家的結構化訪談，以及對近期同行評審文獻和臨床試驗註冊數據的綜合分析，重點關注核酸療法。二手資料涵蓋技術綜述、專利概況和官方監管指導文件，以展現不斷變化的品質、安全性和分析要求的預期。

摘要強調，整合平台能力、監管前瞻性和供應鏈韌性將決定核酸藥物的長期成功。

核酸療法是現代醫學中一個持久且快速發展的支柱，其特點是技術創新、監管學習和不斷變化的營運重點。該領域兼具獨特的科學研究機會和物流複雜性，其成功不僅取決於生物學創新，還取決於生產品質、供應鏈韌性以及與監管機構和支付方的策略協調。整合平台能力、儘早與監管機構溝通並採用地域性配送策略的相關人員，將更有利於把科研潛力轉化為商業性和臨床影響。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • CRISPR-Cas基因編輯遞送技術的進步使得精準體內治療成為可能。
  • 化學修飾的反義寡核苷酸的開發提高了效力和穩定性。
  • 自擴增RNA平台的出現降低了疫苗應用所需的劑量。
  • 將人工智慧整合到個人化核酸藥物設計中，用於標靶治療
  • 非病毒奈米顆粒載體的進步使得siRNA和mRNA療法的系統性遞送成為可能。
  • 不斷完善的法規結構旨在解決長效核酸療法的安全性和有效性問題
  • 透過生技公司與大型製藥公司之間的合作，加速核酸藥物的臨床應用。
  • 擴展基於外泌體的核酸遞送系統，用於靶向細胞內運輸和釋放
  • 推出用於RNA療法規模化生產的微流體控制造平台
  • 用於精準治療顯性遺傳疾病的對偶基因特異性siRNA設計進展

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依藥物類型分類的核酸藥物市場

  • 反義寡核苷酸
  • DNA/RNA適體
  • 基於mRNA的療法
  • 核苷類似物
  • RNA干擾（RNAi）療法
    • 微型RNA（miRNA）
    • 短髮夾RNA（shRNA）
    • 短干擾RNA（siRNA）

9. 依分子類型分類的核酸藥物市場

  • 聚合物
  • 低分子

第10章 依給藥途徑分類的核酸藥物市場

  • 吸入
  • 肌肉內注射
  • 靜脈注射
  • 口服
  • 皮下注射

第11章 依治療領域分類的核酸藥物市場

  • 心血管疾病
  • 感染疾病
    • 細菌感染疾病
    • 黴菌感染疾病
    • 病毒感染疾病
  • 代謝性疾病
  • 神經系統疾病
  • 腫瘤學
    • 骨髓惡性腫瘤
    • 固態腫瘤
  • 罕見疾病

第12章 核酸藥物市場（依最終使用者分類）

  • 學術和研究機構
  • CRO（合約研究組織）
  • 醫院和診所
  • 製藥和生物技術公司

第13章 各地區核酸藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 核酸藥物市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國核酸藥物市場概況

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Alnylam Pharmaceuticals, Inc.
    • Amgen Inc.
    • Arcturus Therapeutics Holdings Inc.
    • Arrowhead Pharmaceuticals, Inc.
    • AstraZeneca PLC
    • Beam Therapeutics Inc.
    • Biogen, Inc.
    • BioMarin Pharmaceutical Inc.
    • BioNTech SE
    • Bluebird Bio, Inc.
    • CRISPR Therapeutics AG
    • CureVac NV
    • Dynavax Technologies Corporation
    • Editas Medicine, Inc.
    • Eli Lilly and Company
    • Evotec SE
    • F. Hoffmann-La Roche Ltd.
    • Generation Bio Co.
    • Gilead Sciences, Inc.
    • GSK PLC
    • Intellia Therapeutics, Inc.
    • Ionis Pharmaceuticals, Inc.
    • Merck & Co., Inc.
    • Moderna, Inc.
    • Novartis AG
    • Novo Nordisk A/S
    • Orna Therapeutics, Inc.
    • Pfizer Inc.
    • ProQR Therapeutics NV
    • Sangamo Therapeutics, Inc.
    • Sanofi SA
    • Sarepta Therapeutics, Inc.
    • Silence Therapeutics PLC
    • Stoke Therapeutics, Inc.
    • Takeda Pharmaceutical Company Limited
    • Vertex Pharmaceuticals Incorporated
    • Voyager Therapeutics, Inc.
    • Wave Life Sciences Ltd.
Product Code: MRR-CA7E340319CE

The Nucleic Acid-Based Drugs Market is projected to grow by USD 93.46 billion at a CAGR of 13.73% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 33.37 billion
Estimated Year [2025] USD 37.76 billion
Forecast Year [2032] USD 93.46 billion
CAGR (%) 13.73%

A concise strategic orientation to nucleic acid therapeutics reflecting the convergence of scientific breakthroughs, regulatory maturation, and industrial scalability

Nucleic acid-based therapeutics have transitioned from niche research curiosities to a mainstream pillar of modern drug development, driven by breakthroughs in delivery systems, chemical modification, and regulatory acceptance. Recent clinical successes and authorization pathways have validated modalities that once faced skepticism, and the scientific community has coalesced around scalable approaches for mRNA, RNA interference, and antisense technologies. These advances have reshaped how developers approach target selection, patient stratification, and platform economics, enabling more agile cycles from discovery to first-in-human trials.

The industry now operates at the intersection of precision biology and industrial biotechnology. Improvements in synthesis, purification, and analytics have reduced historical barriers, while modular platform design has accelerated translational timelines. At the same time, regulatory authorities have matured their frameworks to address modality-specific safety and quality concerns, increasing predictability for developers. As a result, decision-makers must balance scientific opportunity with practical considerations such as manufacturing scalability, supply chain robustness, and global regulatory alignment.

This executive summary synthesizes core trends shaping the field and delivers insights that leaders can apply to R&D prioritization, partnership selection, and operational planning. The aim is to present a concise, evidence-based perspective that supports strategic choices across discovery, clinical development, and commercialization.

How technological platformization, regulatory clarity, and supply chain resilience are reshaping competitive dynamics across the nucleic acid therapeutics landscape

The landscape for nucleic acid therapies has undergone transformative shifts that redefine competitive advantage and program viability. Technological maturation-particularly in delivery vectors, lipid nanoparticle chemistries, and precise chemical modifications-has converted many previously intractable targets into realistic therapeutic opportunities. Concurrently, platform thinking has become central: organizations build reusable development frameworks that shorten timelines and reduce technical risk for subsequent candidates. This platformization has changed investment patterns, as capital increasingly favors entities with demonstrated translational pathways rather than one-off therapeutic concepts.

Regulatory evolution has been equally consequential. Agencies have issued clearer guidances on quality attributes, control strategies, and clinical endpoints specific to nucleic acid modalities. This greater clarity reduces regulatory uncertainty and supports parallel investments in manufacturing and analytic capabilities. At the same time, the ecosystem of contract development and manufacturing organizations has expanded and specialized, enabling smaller developers to access GMP production and advanced analytics without owning large capital footprints.

Geopolitical influences and supply chain considerations now play a larger role in project planning. Sourcing of raw materials, specialized reagents, and instrumentation is more strategic, and companies actively diversify suppliers and regionalize certain production steps to mitigate disruption risk. Together, these shifts emphasize adaptability, resilience, and the importance of integrating scientific, regulatory, and operational strategies early in program planning.

Assessing how tariff dynamics are driving supply chain regionalization, cost reallocation, and strategic shifts in sourcing and manufacturing for nucleic acid therapies

Trade policy changes and the prospect of elevated tariffs can have a cumulative impact on the economics and operational planning of developers and suppliers in the nucleic acid sector. Increased import duties affect the cost base for critical inputs such as modified nucleotides, lipid components, chromatography resins, and specialized single-use consumables. When upstream input costs rise, organizations face pressure to reallocate budgets, prioritize programs with clearer value propositions, or accelerate localization of supply chains to preserve margin and timeline certainty.

Beyond direct cost implications, tariffs can influence strategic behavior. Companies may respond by reconfiguring supply chains to reduce cross-border movements of high-value components, investing in domestic manufacturing capacity to avoid tariff exposure, or renegotiating supplier contracts to shift risk. These adjustments carry operational lead times and capital implications; decisions to insource or regionalize production require rigorous assessment of technical feasibility, regulatory implications, and long-term demand stability.

Tariff pressure also affects collaboration models and licensing negotiations. When manufacturing costs and timelines become less predictable, counterparties increasingly structure agreements with contingency clauses and staged milestones tied to supply stability. For organizations that depend on global networks for materials and services, proactive scenario planning is essential to maintain development momentum. Ultimately, the cumulative impact of tariffs is not solely economic; it reshapes strategic priorities, accelerates regional manufacturing initiatives, and heightens the value of supply chain visibility and contractual flexibility.

Deep segmentation insights connecting drug modality, molecule class, administration route, therapeutic focus, and end-user behaviors to strategic R&D and commercialization choices

Segmentation analysis reveals divergent dynamics across modalities, molecular classes, administration routes, therapeutic areas, and end users that require differentiated strategies. Based on drug type, developers must balance the unique technical demands of antisense oligonucleotides, DNA/RNA aptamers, mRNA-based therapeutics, nucleoside analogs, and RNA interference therapeutics, with RNA interference further subdivided into microRNA, short hairpin RNA, and short interfering RNA; platform investments that favor modular chemistry and delivery approaches can unlock multiple subtypes within this spectrum. Based on molecule type, decision frameworks differ for large molecules compared to small molecules, influencing manufacturing complexity, analytical control strategies, and storage logistics.

Route of administration is a critical determinant of formulation strategy and commercial positioning; inhalation, intramuscular, intravenous, oral, and subcutaneous routes each impose distinct delivery, stability, and patient adherence considerations that influence clinical design and manufacturing specifications. Therapeutic area segmentation highlights how scientific and commercial risk profiles vary: cardiovascular, infectious, metabolic, neurological, oncology, and rare diseases each present different biomarker needs, regulatory pathways, and patient populations, with infectious disease indication suites spanning bacterial, fungal, and viral infections and oncology distinguished by hematologic malignancies versus solid tumors. Based on end-user, utilization patterns and procurement models diverge between academic and research institutes, contract research organizations, hospitals and clinics, and pharmaceutical and biotechnology companies, shaping demand for specialized services, analytic packages, and partnership models.

Collectively, these segmentation lenses enable tailored go-to-market and R&D strategies. Portfolio prioritization should align modality strengths with unmet clinical needs and operational readiness, while manufacturing and quality investments must be matched to anticipated administration routes and end-user requirements to minimize translational friction.

How regional strengths and regulatory nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific determine where innovation, manufacturing, and commercialization accelerate

Regional dynamics are defining where innovation, production, and commercialization momentum concentrate, requiring geographically informed strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, a combination of dense biotech clusters, capital availability, and regulatory agility drives robust early-stage innovation and high transaction activity for partnerships and spinouts. Clinical trial infrastructures and patient recruitment efficiencies support rapid proof-of-concept studies, while domestic manufacturing investments are increasingly prioritized to manage supply chain exposure and tariff risk.

Across Europe, the Middle East & Africa, regulatory harmonization efforts and specialized public-private initiatives support translational pipelines, yet developers must navigate heterogeneous national reimbursement frameworks and varied clinical trial ecosystems. European manufacturing capacity emphasizes quality and technical specialization, often in close collaboration with academic centers to translate platform science. In the Asia-Pacific region, rapid expansion of technical capabilities, competitive manufacturing costs, and growing clinical capacities create attractive conditions for scale-up and late-phase development. Regional regulatory agencies are progressively modernizing frameworks and expanding expedited pathways, and local demand for innovative therapies is rising alongside government investments in biotech infrastructure.

Successful players tailor engagement models by region, aligning partnerships, manufacturing footprints, and regulatory strategies with local strengths. Executing regional playbooks that account for clinical operations, supply chain logistics, and market access nuances will determine the speed and sustainability of commercial rollouts.

Strategic company archetypes and partnership imperatives that dictate which players will accelerate development, enable scalability, and capture commercial value

Competitive landscapes are shaped by a mix of vertically integrated developers, specialist platform providers, contract development and manufacturing organizations, and reagent and instrument suppliers that together form a dense ecosystem. Leading developers differentiate through platform repeatability, demonstrated clinical translation, and the ability to secure strategic partnerships that de-risk late-stage development. Specialist platform providers that offer delivery systems, novel chemistries, or advanced analytics gain outsized influence because they enable multiple therapeutic programs and reduce technical uncertainty for partners.

Contract development and manufacturing organizations remain pivotal, providing access to GMP production, scale-up expertise, and regulatory support-particularly for organizations that prefer asset-light models. Suppliers of critical raw materials and analytical instruments hold strategic importance; their quality, lead times, and geographic footprint directly influence program timelines. Additionally, service providers offering regulatory intelligence, clinical operations tailored to nucleic acid modalities, and market access consulting play an increasingly central role in shaping successful launch strategies.

For decision-makers evaluating partnerships or M&A, the most attractive targets combine strong technical differentiation, reproducible manufacturing processes, and embedded regulatory experience. Assessments should prioritize proven scalability, IP robustness, and the flexibility to support multiple modalities across therapeutic areas.

High-impact recommendations for leaders to convert technological advances into operational resilience, regulatory readiness, and commercial execution

Industry leaders should adopt targeted strategies that align scientific capability with operational resilience and commercial clarity. First, prioritize platform investments that enable reuse across indications and modalities; such platforms reduce marginal development risk and accelerate next-generation programs. Second, build supply chain visibility and diversify suppliers for critical inputs, while exploring regional manufacturing partnerships to mitigate tariff and logistic exposure. Third, integrate regulatory and quality expertise early in program design to streamline comparability, release testing, and CMC timelines.

In parallel, structure partnerships and commercial agreements to reflect supply and regulatory uncertainties, using milestone-based frameworks, shared-risk manufacturing arrangements, and flexible licensing terms. Invest in translational analytics and biomarker strategies to sharpen patient selection and strengthen value dossiers for payers. Operationally, expand capabilities in advanced analytics, process characterization, and digital quality systems to improve batch consistency and support regulatory confidence. Finally, cultivate a talent pipeline that blends molecular biology, process engineering, and regulatory science, ensuring that cross-functional teams can translate platform innovations into reliable clinical and commercial outputs.

Adopting these actions will help organizations convert scientific advances into durable, scalable programs while preserving optionality amid shifting policy and market conditions.

A transparent multi-method research methodology combining expert interviews, technical literature, regulatory reviews, and scenario analysis to validate key insights

The research underpinning this summary draws on a multi-method approach combining primary and secondary evidence to ensure robustness and relevance. Primary inputs included structured interviews with developers, manufacturing specialists, and regulatory experts, as well as synthesis of recent peer-reviewed literature and clinical trial registries focused on nucleic acid modalities. Secondary sources encompassed technological reviews, patent landscapes, and public regulatory guidance documents to map evolving expectations around quality, safety, and analytical requirements.

Analytic methods integrated thematic synthesis of expert interviews with comparative assessments of manufacturing pathways, supply chain configurations, and route-of-administration considerations. Scenario analysis was employed to evaluate the operational implications of trade policy shifts and supply disruptions, while cross-regional comparisons identified regulatory and infrastructure differentials that influence program timelines. Quality control procedures included source triangulation, expert validation of key inferences, and a transparency log documenting data provenance and methodological choices.

This mixed-methods approach balances depth and breadth, providing a defensible foundation for strategic recommendations and enabling targeted follow-up analyses tailored to specific programs or operational questions.

Concluding synthesis emphasizing that integrated platform capabilities, regulatory foresight, and supply chain resilience determine long-term success in nucleic acid therapeutics

Nucleic acid therapeutics represent a durable and rapidly evolving pillar of modern medicine, characterized by technological innovation, regulatory learning, and shifting operational priorities. The field presents a unique combination of scientific opportunity and logistical complexity: success depends not only on biological innovation but also on manufacturing quality, supply chain resilience, and strategic alignment with regulatory and payer pathways. Stakeholders that integrate platform capabilities, early regulatory engagement, and geographically aware supply strategies are best positioned to convert scientific promise into commercial and clinical impact.

Moving forward, organizations should treat platform development and operational readiness as co-equal strategic objectives. By doing so, they can retain the agility to pursue diverse indications while ensuring that late-stage requirements do not create bottlenecks. The ability to anticipate policy shifts, diversify supply channels, and craft flexible partnerships will determine which programs progress efficiently and which face avoidable delays. Ultimately, the most successful actors will be those that combine deep scientific expertise with disciplined execution across manufacturing, regulatory, and commercial domains.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in CRISPR-Cas gene editing delivery techniques for precise in vivo therapies
  • 5.2. Development of chemically modified antisense oligonucleotides with improved potency and stability
  • 5.3. Emergence of self-amplifying RNA platforms reducing dosage requirements in vaccine applications
  • 5.4. Integration of artificial intelligence in designing personalized nucleic acid drug sequences for targeted therapies
  • 5.5. Progress in non-viral nanoparticle carriers enabling systemic delivery of siRNA and mRNA therapeutics
  • 5.6. Regulatory frameworks evolving to address safety and efficacy of long-acting nucleic acid modalities
  • 5.7. Collaborations between biotech firms and large pharma accelerating clinical translation of nucleic acid drugs
  • 5.8. Expansion of exosome-based nucleic acid delivery systems for targeted intracellular transport and release
  • 5.9. Adoption of microfluidic manufacturing platforms for scalable production of RNA-based therapeutics
  • 5.10. Advances in allele-specific siRNA design enabling treatment of dominant genetic disorders with high precision

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Nucleic Acid-Based Drugs Market, by Drug Type

  • 8.1. Antisense Oligonucleotides
  • 8.2. DNA/RNA Aptamers
  • 8.3. mRNA-Based Therapeutics
  • 8.4. Nucleoside Analogs
  • 8.5. RNA Interference (RNAi) Therapeutics
    • 8.5.1. MicroRNA (MiRNA)
    • 8.5.2. Short Hairpin RNA (ShRNA)
    • 8.5.3. Short Interfering RNA (SiRNA)

9. Nucleic Acid-Based Drugs Market, by Molecule Type

  • 9.1. Large Molecule
  • 9.2. Small Molecule

10. Nucleic Acid-Based Drugs Market, by Route of Administration

  • 10.1. Inhalation
  • 10.2. Intramuscular
  • 10.3. Intravenous
  • 10.4. Oral
  • 10.5. Subcutaneous

11. Nucleic Acid-Based Drugs Market, by Therapeutic Area

  • 11.1. Cardiovascular Diseases
  • 11.2. Infectious Diseases
    • 11.2.1. Bacterial Infections
    • 11.2.2. Fungal Infections
    • 11.2.3. Viral Infections
  • 11.3. Metabolic Disorders
  • 11.4. Neurological Disorders
  • 11.5. Oncology
    • 11.5.1. Hematologic Malignancies
    • 11.5.2. Solid Tumors
  • 11.6. Rare Diseases

12. Nucleic Acid-Based Drugs Market, by End-User

  • 12.1. Academic & Research Institutes
  • 12.2. Contract Research Organizations
  • 12.3. Hospitals & Clinics
  • 12.4. Pharmaceutical & Biotechnology Companies

13. Nucleic Acid-Based Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Nucleic Acid-Based Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Nucleic Acid-Based Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Alnylam Pharmaceuticals, Inc.
    • 16.3.2. Amgen Inc.
    • 16.3.3. Arcturus Therapeutics Holdings Inc.
    • 16.3.4. Arrowhead Pharmaceuticals, Inc.
    • 16.3.5. AstraZeneca PLC
    • 16.3.6. Beam Therapeutics Inc.
    • 16.3.7. Biogen, Inc.
    • 16.3.8. BioMarin Pharmaceutical Inc.
    • 16.3.9. BioNTech SE
    • 16.3.10. Bluebird Bio, Inc.
    • 16.3.11. CRISPR Therapeutics AG
    • 16.3.12. CureVac N.V.
    • 16.3.13. Dynavax Technologies Corporation
    • 16.3.14. Editas Medicine, Inc.
    • 16.3.15. Eli Lilly and Company
    • 16.3.16. Evotec SE
    • 16.3.17. F. Hoffmann-La Roche Ltd.
    • 16.3.18. Generation Bio Co.
    • 16.3.19. Gilead Sciences, Inc.
    • 16.3.20. GSK PLC
    • 16.3.21. Intellia Therapeutics, Inc.
    • 16.3.22. Ionis Pharmaceuticals, Inc.
    • 16.3.23. Merck & Co., Inc.
    • 16.3.24. Moderna, Inc.
    • 16.3.25. Novartis AG
    • 16.3.26. Novo Nordisk A/S
    • 16.3.27. Orna Therapeutics, Inc.
    • 16.3.28. Pfizer Inc.
    • 16.3.29. ProQR Therapeutics N.V.
    • 16.3.30. Sangamo Therapeutics, Inc.
    • 16.3.31. Sanofi SA
    • 16.3.32. Sarepta Therapeutics, Inc.
    • 16.3.33. Silence Therapeutics PLC
    • 16.3.34. Stoke Therapeutics, Inc.
    • 16.3.35. Takeda Pharmaceutical Company Limited
    • 16.3.36. Vertex Pharmaceuticals Incorporated
    • 16.3.37. Voyager Therapeutics, Inc.
    • 16.3.38. Wave Life Sciences Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NUCLEIC ACID-BASED DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. NUCLEIC ACID-BASED DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NUCLEIC ACID-BASED DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DNA/RNA APTAMERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DNA/RNA APTAMERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DNA/RNA APTAMERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DNA/RNA APTAMERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DNA/RNA APTAMERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DNA/RNA APTAMERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MRNA-BASED THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MRNA-BASED THERAPEUTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MRNA-BASED THERAPEUTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MRNA-BASED THERAPEUTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MRNA-BASED THERAPEUTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MRNA-BASED THERAPEUTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MICRORNA (MIRNA), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MICRORNA (MIRNA), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MICRORNA (MIRNA), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MICRORNA (MIRNA), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MICRORNA (MIRNA), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MICRORNA (MIRNA), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT INTERFERING RNA (SIRNA), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT INTERFERING RNA (SIRNA), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT INTERFERING RNA (SIRNA), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT INTERFERING RNA (SIRNA), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT INTERFERING RNA (SIRNA), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT INTERFERING RNA (SIRNA), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY LARGE MOLECULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY LARGE MOLECULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY LARGE MOLECULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY LARGE MOLECULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY LARGE MOLECULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY LARGE MOLECULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY FUNGAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY FUNGAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY FUNGAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY FUNGAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RARE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION